当前位置: X-MOL 学术N. Engl. J. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2022-07-13 , DOI: 10.1056/nejmoa2206125
Stephen M Ansell 1 , John Radford 1 , Joseph M Connors 1 , Monika Długosz-Danecka 1 , Won-Seog Kim 1 , Andrea Gallamini 1 , Radhakrishnan Ramchandren 1 , Jonathan W Friedberg 1 , Ranjana Advani 1 , Martin Hutchings 1 , Andrew M Evens 1 , Piotr Smolewski 1 , Kerry J Savage 1 , Nancy L Bartlett 1 , Hyeon-Seok Eom 1 , Jeremy S Abramson 1 , Cassie Dong 1 , Frank Campana 1 , Keenan Fenton 1 , Markus Puhlmann 1 , David J Straus 1 ,
Affiliation  

New England Journal of Medicine, Ahead of Print.


中文翻译:

Brentuximab Vedotin 在 III 期或 IV 期霍奇金淋巴瘤中的总体存活率

新英格兰医学杂志,印刷前。
更新日期:2022-07-14
down
wechat
bug